| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Cotreatment of ER stress-inducers or proteasome inhibitors with sorafenib decreased the spliced XBP1 expression, a downstream of unfolded protein response, but lenvatinib increased spliced XBP1. Sorafenib exacerbated autophagic flux more than lenvatinib. Sorafenib and lenvatinib decreased cell viability cotreated with ER stress inducers.
|
